STOPCAP M1, abiraterone, systematic review and aggregate data meta-analysis

Addition of abiraterone to standard of care in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

Does early abiraterone improve survival for men with metastatic hormone prostate cancer?

What was this study about?

systematic review and meta-analysis was carried out bringing together trials that looked at whether adding abiraterone to androgen deprivation therapy (ADT), improved survival in men with metastatic prostate cancer.

What difference did this study make?

The addition of abiraterone to ADT showed an improvement in survival and progression-free survival in men whose disease had spread (metastatic) and offers an alternative to docetaxel, for men who are starting treatment for the first time.

Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. European Journal of Cancer 2017;84:88-101

Type of study

Meta-analyses

Contact details

mrcctu.stopcapm1@ucl.ac.uk

Who funded the study?

Medical Research Council, UK

When did it take place?

This study was fully published in 2017 and brought together the results of two trials that were carried out between 2011 and 2014.

Where did it take place?

This study was done at the MRC Clinical Trials Unit at UCL but brings together the results of two trials from Europe.

Who was included?

This study brought together 2 trials (2201 patients) that studied the addition of abiraterone to ADT.

Smarter Studies. Global Impact. Better Health.

The MRC Clinical Trials Unit (MRC CTU) at UCL is at the forefront of resolving internationally important questions in infectious diseases and cancer, and delivering swifter and more effective translation of scientific research into patient benefits.